Long-term use of bisphosphonates in osteoporosis

References

1. ↵
   1. Alwahhabi BK,
   2. Alsuwaine BA

   (2017) Long-term use of bisphosphonates in osteoporosis. Saudi Med J 38:604–608.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Feldstein A,
   2. Black D,
   3. Perrin N,
   4. Rosales A,
   5. Friess D,
   6. Boardman D,
   7. et al.

   (2012) Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 27:977–986.

   OpenUrlCrossRefPubMed
3. ↵
   1. Meier R,
   2. Perneger T,
   3. Stern R,
   4. Rizzoli R,
   5. Peter R

   (2012) Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172:930–936.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. General Authority for Statistics

   Central Department of Statistics, Available from URL: http://www.cdsi.gov.sa. [cited 2017 June 2017].
5. ↵
   1. Shane E,
   2. Burr D,
   3. Ebeling PR,
   4. Abrahamsen B,
   5. Adler RA,
   6. Brown TD,
   7. et al.

   (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Tan S,
   2. Koh S,
   3. Goh S,
   4. Howe T

   (2011) Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int 22:2211–2212.

   OpenUrlCrossRefPubMed
7. ↵
   1. Mahjoub Z,
   2. Jean S,
   3. Leclerc JT,
   4. Brown JP,
   5. Boulet D,
   6. Pelet S,
   7. et al.

   (2016) Incidence and characteristics of atypical femoral fractures: Clinical and Geometrical Data. J Bone Miner Res 31:767–776.

   OpenUrlCrossRef